Pharma Sales in China – How to Assess Trends and Potential Revenues, Benefiting Your Influence What does the future hold for China’s pharma market? Can it sustain high growth? Visiongain’s new report gives you forecasted revenues there to 2025. Our work explains medical and technological trends, prospects and commercial opportunities.
China retains great potential for sales of prescription drugs and OTC medicines. Our updated study gives data and multilevel revenue predictions. There you investigate activities of domestic and international companies, assessing prospects for their expanding market.
Our analysis shows you the most lucrative parts of Chinese pharmaceutical sales. Read on, then, to explore that market and see what revenue it could achieve in future.
Forecasts and other analyses to help you stay ahead on China’s pharma market Our new survey shows you revenue predictions to 2025, historical data, growth rates and market shares. It explores business outlooks, trends and leading companies. With that work you gain 76 tables, 82 charts and two interviews with organisations.
Is finding data on Chinese healthcare proving difficult? Now you can stay ahead in knowledge, benefiting your research, analyses, plans, decisions and authority. The following sections explain how our investigation helps your work.
Sales predictions for the Chinese drug market and its segments – discover sales potentials Along with revenue prediction for the overall Chinese pharma market, our study shows individual forecasting to 2025 for these therapeutic submarkets: • Infectious diseases – antibiotics and other anti-infective products • Cancer – applications in oncology, anticancer agents • Cardiovascular disorders – with sub-forecasts for hypertension and dyslipidaemia • Diabetes therapies • Respiratory diseases – with sub-forecasts for COPD and asthma treatments • Autoimmune conditions • Central nervous system (CNS) disorders – with sub-forecasting for antidepressants • Other medical needs (grouped).
Our report also gives individual revenue forecasts to 2025 by product class and sales channel: • Small-molecule pharmaceuticals – with sub forecasts for original-branded medicines prescription drugs and generics • Biological drugs – with sub forecasts for novel biologics, biosimilars and vaccines • Traditional Chinese medicines (TCM) • Hospitals • Retail pharmacies • Clinics and other channels • Over-the-counter (OTC) products.
China remains an exciting and important market for pharmaceutical companies. Our study shows you what is possible there from 2015, including high demand for treatments.
For prominent diseases in China, our survey lets you assess prevalence and incidence rates to 2025. Discover treatment opportunities for pharmaceutical companies from 2015.
With our analysis you explore what influences Chinese healthcare industries and markets.
Trends, characteristics and other forces shaping the Chinese pharma market Our report discusses issues, regulations and other events influencing Chinese healthcare and related industries from 2015: • Epidemiological trends – explore treatment needs underpinning Chinese healthcare • Institutions regulating the pharmaceutical industry – policy generation • Chinese healthcare reform – initiatives, e.g. Healthy China 2020, affecting drug producers and marketers • Opportunities in treating chronic diseases, including HIV and hepatitis • Protection of intellectual property – progress and challenges • Sales outlets – distribution channels most important from 2015 to 2025.
Our study also discusses other aspects of medical businesses in China, including these developments: • Manufacturing and R&D, including biotechnology and trends for venture capital • Healthcare funding – driving and restraining forces • Discussion of the Anhui model and its implications • Investment in rural healthcare – high demands needing served, giving opportunities • Branded generics – their prospects for expanding treatment coverage • Biosimilar drug manufacturers – harnessing China’s strengths in biopharma.
With our investigation you explore technological, economic, social and political trends. You also analyse that market’s strengths, weaknesses, opportunities and threats. Discover, from 2015 to 2025, what the future holds for pharma companies operating in China.
Leading companies – domestic and foreign – and overall 2019 market value What happens next? Our report predicts overall pharma sales in China will reach $227bn in 2019, expanding onwards to 2025. Explore what is possible in that vast, fast-growing market.
Our study covers these multinational companies and other foreign organisations developing that market: • AbbVie • Eli Lilly • GlaxoSmithKline • AstraZeneca • Johnson & Johnson • Novo Nordisk • Novartis • Bayer • Pfizer • Roche • Merck & Co.
Our survey also discusses leading Chinese pharma companies, with ranking of the top 50 by revenue. See the roles they serve and their outlooks for the future. These and many other domestic firms appear in the study: • Guangzhou Pharmaceutical Holdings • Shanghai Pharmaceuticals • Yunnan Baiyao • Harbin Pharmaceuticals • Xiuzheng Pharmaceutical Group • Sinopharm.
In our report you also discover interviews with other authorities on Chinese pharma, helping you stay ahead for commercial insight.
From 2015 there will arise many opportunities in China for drug companies to develop their businesses. Our work shows you the medical, technological and commercial possibilities. Assess what is possible in Chinese healthcare to 2025.
Ways Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025 helps you In these main ways, our investigation benefits your research, analysis and plans, helping you stay ahead: • Pharma revenues in China to 2025 at overall national level and for 26 submarkets – assess outlooks for investments, production, marketing and sales • Epidemiological trends – see treatment needs by disease, assessing data on present and future healthcare demands • Prospects for established competitors, rising companies and new entrants – explore results, R&D, technologies, strategies and outlooks for success • Interviews with authorities on Chinese pharma – assess opinions and other qualitative analyses to help you compete and succeed.
That report, by Visiongain’s in-house UK-based analysts, gives knowledge to benefit your research, analyses, decisions and proposals. Get data leading companies depend on.
Information there found nowhere else, benefiting your knowledge and influence Our study gives independent analysis. There you receive predictions found only in our work, seeing where technological and financial prospects are most rewarding.
With our investigation you are less likely to fall behind in knowledge or miss opportunity. See there how you could help your research, planning and presentations, also saving time and benefiting your reputation for commercial insight.
Our knowledge costs only a tiny fraction of potential profits from your understanding and harnessing the vast Chinese market. Find its growth potential and see how you could gain.
Trying our report now lets you discover where the money lies in Chinese pharma Our new study is for everyone analysing Chinese healthcare. There you find data, trends, opportunities and sales predictions. Avoid falling behind – get our new report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 The Chinese Pharmaceutical Market, 2015-2025 1.2 Chinese Pharmaceutical Market: Segmentation, 2015 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Main Questions Answered by This Analytical Study 1.6 Who is This Report For? 1.7 Methods of Research and Analysis 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Reports 1.10 About Visiongain
2. Chinese Healthcare: Overview, 2015 2.1 China: Demographic Indicators Overview, 2015 2.2 Chinese Healthcare System: Overview, 2015 2.3 Analysis of China’s Healthcare Expenditure 2.4 The Chinese System: Who Really Pays the Bill? 2.5 State Bodies Regulating the Chinese Pharmaceutical Market 2.6 Healthy China 2020: The Government’s Long-term Plan 2.7 Analysis of the Potential of ‘Healthy China Initiative’, 2015 2.8 The Big Debate About Healthcare Funding
3. Chinese Pharmaceutical Market: Discussions and Predictions, 2015-2025 3.1 Chinese Pharmaceutical Market: The Second Biggest Market in the World, 2014 3.2 Chinese Pharmaceutical Market: Overall Revenue Forecast, 2015-2025
4. Medical Treatment Needs in China, 2015-2025 4.1 Disease Prevalence in China, 2015-2025 4.2 Disease Incidence in China, 2015-2025 4.3 Disease Mortality Rates in China, 2015-2025 4.3.1 Top 5 Broad Causes of Death in China 4.3.2 Stoke and Cancers: China’s Top Killers 4.3.3 Top Causes of Death in China: Mortality Projections, 2015-2025
5. Chinese Pharmaceutical Market: Leading Therapeutic Areas, 2015-2025 5.1 Leading Therapeutic Areas in the Chinese Pharmaceutical Market: Overview, 2014 5.2 Chinese Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2015-2025 5.3 Chronic Diseases Overtook the Infectious Diseases Segment, 2015-2025 5.4 Expanding China’s EDL: Reimbursement Focus on Key Therapies 5.5 Cardiovascular Therapeutic Segment: Overview, 2015 5.5.1 Cardiovascular Drugs Market: Forecast, 2015-2025 5.5.2 Hypertension in China Reaches Unprecedented Levels 5.5.3 Chinese Hypertension Drugs Market Continuing to Thrive: Forecast, 2015-2025 5.5.4 Chinese Hypertension Drugs Market: Leading Products 5.5.5 Treatment of Chinese Hypertensive Patients 5.5.6 Dyslipidaemia: Overview of China’s Most Prevalent Disease 5.5.7 Treatment of Dyslipidaemia Affected by Reimbursement Issues 5.5.8 Chinese Dyslipidaemia Market Prospects: Forecast, 2015-2025 5.5.9 Chinese Cardiovascular Disease Segment: Major Focus of Western Companies 5.5.10 Big Pharma Companies Dominate the Chinese Hypertension Drugs Market 5.5.11 Increasing Domestic Company Presence in the Cardiovascular Therapeutic Segment 5.5.12 Drivers and Restraints for the Chinese Cardiovascular Drugs Market, 2015 5.6 Anticancer Therapeutic Segment: Overview, 2015 5.6.1 Anticancer Drugs will be the Largest Segment of the Chinese Pharmaceutical Market by 2025: Forecast, 2015-2025 5.6.2 Cancer Incidence Boosts the Eminence of China’s Anticancer Drugs Market, 2015-2025 5.6.3 Targeted Anticancer Therapeutics Making Progress in China 5.6.4 Chinese Pharma Companies Focusing on Anticancer Drugs 5.6.5 Eli Lilly and Innovent Biologics’ Strategic Alliance: New Big Player in China’s Anticancer Market? 5.6.6 Improved Healthcare Coverage for Cancer Patients Promises Strong Revenue Stream from Anticancer Drugs 5.6.7 Marketing Innovative Anticancer Drug in China – Example from Roche 5.6.8 Negative Impact of Late Cancer Diagnosis 5.6.9 Cost of Treatment Critical for the Choice of Anticancer Medicine 5.6.10 Tailored Anticancer Treatment for the Chinese Market - Notable Companies and their Developments 5.6.11 Biomarker Testing in China – What Improvement is Possible? 5.6.12 Drivers and Restraints for the Anticancer Drugs Segment, 2015 5.7 Infectious Disease Therapeutics: Overview, 2015 5.7.1 Infectious Disease Drugs Market: Forecast, 2015-2025 5.7.2 What Makes China Prominent for Antibiotics Use: Analysis of Cephalosporin, 2015 5.7.3 China’s Infectious Disease Market Dominated by Domestic Companies 5.7.4 Antibiotics Over-use Reported in China: Causes and Results 5.7.5 HIV and Hepatitis in China: Growing Therapeutic Areas Worth Watching 5.7.6 Hepatitis C Drug Challenges 5.7.7 Drivers and Restraints for the Infectious Diseases Pharma Segment, 2015 5.8 Diabetes Therapeutic Segment: Overview, 2015 5.8.1 Diabetes Drugs Market: Forecast, 2015-2025 5.8.2 Multinational Companies in the Chinese Diabetes Drug Market: Overview and Analysis, 2015 5.8.3 Domestic Companies Competing in the Chinese Diabetes Drug Market 5.8.4 Diabetes in China: Challenges and Opportunities 5.8.5 Drivers and Restraints for the Diabetes Drugs Segment, 2015 5.9 Respiratory Therapeutic Segment: Overview, 2015 5.9.1 Respiratory Disease Drugs Market: Forecast, 2015-2025 5.9.2 Chinese COPD Market: How Profitable Could it Be? 5.9.3 Chinese COPD Treatments Market: Predicted Revenue Increase – Forecast, 2015-2025 5.9.4 Chinese Asthma Drugs Market to Give Dependable Growth: Forecast, 2015-2025 5.9.5 Domestic Respiratory Drug Producers 5.9.6 Leading Respiratory Disease Drugs in China 5.9.7 AstraZeneca Sustains Market Penetration through Collaboration and Research 5.9.8 Drivers and Restraints for the Respiratory Diseases Segment, 2015 5.10 Central Nervous System (CNS) Therapeutics: Overview, 2015 5.10.1 CNS Drugs Market: Forecast, 2015-2025 5.10.2 By 2025 Over 7 Million People in China will Suffer from Depression: 5.10.3 Depression Drugs Market in China will Reach a 25% Annual Growth Rate: Forecast, 2015-2025 5.10.4 Domestic Companies in China’s CNS Disorders Market 5.10.5 China’s Aging Population: Driver for the CNS Segment 5.10.6 Rise of Dementia and Alzheimer’s Disease Presents Strong Market Opportunity 5.10.7 High Demand for Pain Relief Medicines in China 5.10.8 Drivers and Restraints for the CNS Drugs Segment, 2015 5.11 Immunomodulators: Overview, 2015 5.11.1 Autoimmune Drugs Market: Forecast, 2015-2025 5.11.2 Notable Chinese Companies in the Immunomodulators Market 5.11.3 Challenges Erode the Immunomodulator Market’s Potential 5.11.4 Immunomodulator Treatments to Gain Momentum in China 5.11.5 Drivers and Restraints for the Autoimmune Drugs Segment, 2015
6. Chinese Pharmaceutical Market: Leading Product Classes, 2015-2025 6.1 Product Classes in the Chinese Pharmaceutical Market: Overview, 2014 6.2 Chinese Pharmaceutical Market: Product Classes Forecasts, 2015-2025 6.3 Small Molecules: Overview, 2015 6.3.1 Chinese Small Molecule Drugs Market: Forecast, 2015-2025 6.3.2 Generics: Growth Engine for the Small Molecules Segment 6.3.3 Healthcare Reform Provides Opportunities for Original-Branded and Generic Drugs 6.3.4 Drivers and Restraints for the Small Molecule Treatments Market in China, 2015 6.4 Traditional Chinese Medicine (TCM): Overview, 2015 6.4.1 Traditional Chinese Medicine Market: Forecast, 2015-2025 6.4.2 Investments in TCM Development: Analysis of China’s TCM Market, 2015 6.4.3 Expansion of the TCM Market 6.4.4 Leading Chinese Companies in the TCM Segment, 2015 6.4.5 Drivers and Restraints for the Traditional Chinese Medicines Market, 2015 6.5 Chinese Biological Drugs Market: Overview, 2015 6.5.1 Chinese Biologics Market: Forecasts, 2015-2025 6.5.2 Branded Biologics Perform Well in China: Forecast, 2015-2025 6.5.3 Biomedicines Set for Strategic Growth: Analysis of China’s Fastest Growing Product Class, 2015 6.5.4 Roche Finding a Way Forward in China with Branded Biologics 6.5.5 Chinese Vaccines Market: Overview, 2015 6.5.6 China: the World’s Fifth Largest Vaccine Market 6.5.7 Chinese Vaccines Segment Loses Share: Forecast, 2015-2025 6.5.8 Companies Dominating the Vaccines Market in China 6.5.9 Domestic Manufacturer Supplies 80% of Vaccines in China 6.5.10 Multinational Companies Compete for a Share of the Chinese Vaccines Market 6.5.11 Hepatitis B Vaccine in China – a Story of Success 6.5.12 Chinese Biosimilars Market: Overview, 2015 6.5.13 Chinese Biosimilars Market: Forecast, 2015-2025 6.5.14 Biosimilars Account for Small Proportion of Biological Drug Revenues in China: When will this Change? 6.5.15 Chinese Biosimilar Development Guidelines Set for Release 6.5.16 Leading Chinese Biosimilar Manufacturers 6.5.17 Market Access for Biosimilars: Critical to Leverage Opportunities in China 6.5.18 Drivers and Restraints of the Chinese Biologics Market
7. Chinese Pharmaceutical Market: Leading Drug Types, 2015-2025 7.1 Drug Types in the Chinese Market: Overview, 2014 7.2 Growth Forecasts for Leading Drug Types in China, 2015-2025 7.3 Generic Drugs Dominate the Chinese Pharmaceutical Market 7.3 Generic Prescription Drugs Market in China: Forecast, 2015-2025 7.3.1 Chinese Pharmaceutical Market Structure Favours Generics’ Sales 7.3.2 Which Drugs Benefit More from the Government’s Healthcare Reform: Original-Patented or Generic? 7.3.3 Many Chinese Patients Favour Branded Generics 7.3.4 AstraZeneca and Pfizer: Leaders in the Chinese Branded Generics Market 7.4 Chinese Over-the-Counter (OTC) Medicines Market: Forecast, 2015-2025 7.4.1 Chinese OTC Drugs Segment: Insights and Analysis of the Market’s Potential, 2015 7.4.2 China: The World’s Biggest OTC Pharmaceuticals Market 7.4.3 Leading Domestic Companies in the Chinese OTC Market, 2015 7.4.4 Bayer: The Biggest Multinational Player in China’s OTC Market 7.5 Chinese Patented Prescription Drugs Market: Forecast, 2015-2025 7.5.1 Chinese Patented Prescription Drugs Market: Factors Stimulating Sales Growth
8. Chinese Pharmaceutical Market: Sales Channels, 2015-2025 8.1 Chinese Pharmaceutical Market: Sales Channels Overview and Value, 2014 8.2 Chinese Pharmaceutical Market: Sales Channels Forecasts, 2015-2025 8.3 Only Five Domestic Companies Have a Sizable Share of the Chinese Pharma Distribution Market 8.4 Chinese Distribution Channels are Highly Fragmented Compared to Western Counterparts 8.5 Chinese Distribution Channels: Why Consolidation is Essential? 8.6 Shift Towards Consolidation within the Distribution Chain: Key Market Developments 8.7 China’s Drugs Distribution Environment: Issues and Challenges 8.8 Chinese Distribution Value Chain Follows a Complex Model 8.9 Chinese Pharmaceutical Distribution Network Comprises the World’s Largest Sales Force 8.10 Bribery Penalties: Indication of China’s Changing Pharmaceutical Distribution Practices 8.11 Hospital Sales Channels: Forecast, 2015-2025 8.11.1 Hospitals: Foundation of the Chinese Healthcare System 8.11.2 Chinese Public Hospitals: Healthcare Reform’s Priority 8.11.3 How does the Medicines Mark-up Ban Affect Hospitals’ Revenues? 8.12 Retail Pharmacies Channels: Forecast, 2015-2025 8.12.1 Difficulties in Retail Pharmacy Market Estimates 8.12.2 Online Pharmacies: the New Big Market Opportunity in China 8.13 Grassroot Clinics’ Sales Channels: Forecast, 2015-2025 8.13.1 Rural Investment will Facilitate Drug Sales Growth in Grassroot Clinics 8.14 Other Sales Channels: Forecast, 2015-2025 8.14.1 Other Sales Channels: The Grey Pharmaceuticals in China
9. Leading Companies in the Chinese Pharmaceuticals Market, 2015 9.1 Top 50 Domestic Chinese Pharmaceutical Companies, 2014 9.2 China’s Pharma is Highly Fragmented Compared to Other Prominent Markets 9.3 Leading Chinese Contract Research Organisations 9.4 Leading Multinational Companies in the Chinese Pharmaceutical Market: Strategies that Win, 2015 9.4.1 MNC Revenue and Market Share Estimates, 2014 9.4.2 AstraZeneca and Pfizer: Leaders in the Chinese Branded Generics Segment 9.4.3 Bayer – Exceeding $3bn of Pharma Sales in China Possible? 9.4.4 Pfizer’s Strategic Approach in China – Does it Work? 9.4.5 Multinational Contract Research Organisations in China 9.5 New Policies Shift the Market Dynamics for Leading Players 9.6 Emerging Strategies to Boost Drug Sales and Comply with Regulations 9.7 What is Next in China for Multinational Pharma Companies? 9.8 Drivers and Restraints for Big Pharma’s Sales Growth in China, 2015
10. Research Interviews 10.1 Interview with Dr Greg Scott, Founder, ChinaBio Group 10.1.1 Future Prospects for the Chinese Pharmaceutical Market 10.1.2 Cancer is at the Forefront of Drug Development in China 10.1.3 Biologics in China – Biosimilars to Lead the Way 10.1.4 The Anhui Model - Discussion 10.1.5 IP Protection in China - Outlook 10.1.6 Consolidating the Fragmented Chinese Market 10.1.7 Access to the Chinese Pharmaceutical Market 10.2 Interview with Julie Li, Strategy Manager, China Resources Double-Crane Pharmaceuticals, China 10.2.1 Multinational Companies Dominate Drug Discovery in China 10.2.2 Cancer and Chronic Disease are Critical Areas in China 10.2.3 The Impact of Control on Antibacterial Drug Prescriptions 10.2.4 Potential for Consolidation of the Chinese Pharma Industry
11. Qualitative Analysis of the Chinese Pharmaceutical Market, 2015 11.1 Strengths: Increasing Investment in the Healthcare System 11.1.1 The Disease Burden Grows; So Does GDP 11.1.2 Chinese Pharmaceutical Market Still Has Untapped Potential 11.1.3 Progressive Urbanisation Continues to Drive Healthcare Spending 11.1.4 New Policies Recognise the Importance of IP 11.1.5 Research Hub for Asia Pacific and Beyond 11.2 Weaknesses: Imbalance of Resources and Quality Challenges 11.2.1 Healthcare Quality Issues Hit the Chinese Pharmaceutical Market 11.2.2 Highly Fragmented Pharmaceutical Market 11.2.3 Reimbursement and Market Access 11.2.4 Limited First-Class Laboratory Facilities Reported 11.2.5 Regulations and Clinical Trial Research 11.3 Opportunities: Quickly Emerging Volume Growth 11.3.1 Tailored Strategies to Meet the Chinese Pharma Market’s Need 11.3.2 Portfolio Diversification Matters 11.3.3 Enhancing Consolidation Activities 11.3.4 Innovative Biotechnology Sector 11.3.5 Liberal Regulations on Stem Cells Research 11.4 Threats: What if Things Go Wrong in China? 11.4.1 Strong Government Intervention 11.4.2 Anhui Model and its Results 11.5 Social Forces: The Increasing Power of China’s Demographics 11.5.1 The Ageing Dragon 11.5.2 The Obesity Epidemic 11.5.3 Social Changes and Their Effect on China’s Shifting Medical Treatment Patterns 11.6 Technological Factors: Embracing Technology and Increasing R&D Capabilities 11.6.1 National Database and Telemedicine: New Trends Shaping the Industry 11.6.2 Developing China’s R&D Capabilities through Technology 11.6.3 China Has the World’s Largest and Most Affordable Genomic Sequencing Facilities 11.7 Economic Factors: Economic Growth Closely Related to the Chinese Pharmaceutical Market Growth 11.7.1 China’s Rise as an Economic Superpower 11.7.2 Underlying Problems of China’s Economic Growth 11.7.3 How Many Five-Year Plans will Follow? 11.8 Political: The Chinese Government Possesses the Ultimate Power
12. Conclusions 12.1 China’s Healthcare Reform: Crucial Factor for Pharmaceutical Market Growth 12.2 China: the Country Driving Growth for the World’s Pharmaceutical Market, 2015-2025 12.3 Cancer Will Form a Main Therapeutic Segment in the Chinese Pharmaceutical Market 12.4 Generic and OTC Drugs Set to Remain the Main Product Types, but Patented Drugs will Experience Momentum 12.5 Pharmacy Sales are the Next Big Market Opportunity in China 12.6 Domestic Companies Still Dominate the Chinese Pharma Market, Amid Increasing Competition from MNCs 12.7 Concluding Thoughts on the Research and Analysis
List of Tables Table 1.1 Chinese Pharmaceutical Market Forecast by Therapy Area: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025 Table 2.1 China: Demographic Indicators, 2005-2014 Table 2.2 Healthcare Expenditure: Leading Markets and BRIC Countries, Total (%) of GDP, 2005-2013 Table 2.3 Chinese Institutions Regulating the Pharmaceutical and Healthcare Industries in China, 2015 Table 2.4 Chinese Healthcare Reform: Significant Initiatives, 2009-2015 Table 3.1 Regional Pharmaceutical Markets of the World: Market Size ($bn), Market Share (%), 2014 Table 3.2 Chinese Pharmaceutical Market Overall Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025 Table 4.1 Projections of Common Diseases’ Prevalence in China: Prevalence (000s) (%), CAGR (%), 2015-2025 Table 4.2 Projections of Common Diseases’ Incidence in China: Incidence (000s), CAGR (%), 2015-2025 Table 4.3 Top 5 Causes of Death per (000s) in China’s Urban and Rural Areas, 2013 Table 4.4 Top 15 Broad Causes of Death in China: Deaths (000s), Proportion of Overall Deaths (%), 2012 Table 4.5 Top 25 Causes of Death in China: Projected Deaths (000s), Share of Overall Deaths (%), CAGR (%) 2015-2025 Table 5.1 Chinese Pharmaceutical Market by Therapy Area: Market Size ($bn), Market Share (%), 2014 Table 5.2 Chinese Pharmaceutical Market by Therapy Area: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 5.3 Chinese Pharmaceutical Market by Therapy Area: Market Share Forecast (%), 2015-2025 Table 5.4 Selected High Profile New Entrants to China’s 2012 Essential Drugs List Table 5.5 Chinese Cardiovascular Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 5.6 Chinese Hypertension Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025 Table 5.7 Chinese Hypertension Market by Drug Class: Market Size ($bn), Market Share (%), 2014 Table 5.8 Chinese Dyslipidaemia Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025 Table 5.9 Top Companies in the Chinese Hypertension Market: Revenue ($bn), Market Share (%), 2014 Table 5.10 Leading Domestic Chinese Cardiovascular Drug Manufacturers and Their Activities, 2015 Table 5.11 Chinese Anticancer Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 5.12 Projected Incidence of Types of Cancer in China: Incidence (000s), CAGR (%), 2015-2025 Table 5.13 Selected Domestic Chinese Anticancer Drug Manufacturers and Their Activities, 2014 Table 5.14 Chinese Infectious Disease Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 5.15 Chinese Infectious Disease Drugs Market by Drug Class: Market Size ($bn), Market Share (%), 2014 Table 5.16 Domestic Antibacterial Drug Manufacturers and Their Activities, 2015 Table 5.17 Chinese Diabetes Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 5.18 Selected Domestic Chinese Diabetes Drug Manufacturers and Their Activities, 2015 Table 5.19 Chinese Respiratory Disease Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 5.20 Chinese COPD Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025 Table 5.21 Chinese Asthma Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2015-2025 Table 5.22 Selected Domestic Companies in the Respiratory Market and Their Activities, 2015 Table 5.23 Chinese Respiratory Drug Market by Product Class: Sales ($bn), Market Share (%), 2014 Table 5.24 Chinese CNS Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 5.25 Chinese Antidepressants Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Table 5.26 Selected Domestic Companies in the CNS Market and Their Activities, 2015 Table 5.27 Chinese Autoimmune Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 5.28 Selected Chinese Immunomodulator Drug Companies and Their Activities, 2015 Table 6.1 Chinese Pharmaceutical Market by Product Class: Market Size ($bn), Market Share (%), 2014 Table 6.2 Chinese Pharmaceutical Market by Product Class: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 6.3 Chinese Small Molecule Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 6.4 Chinese Small Molecule Drugs Market by Product Type: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 6.5 Traditional Chinese Medicine Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 6.6 Selected TCM Manufacturers and their Activities, 2015 Table 6.7 Chinese Biological Drugs Market by Product Type: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 6.8 Chinese Branded Biologics Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 6.9 Chinese Vaccines Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 6.10 Chinese Biosimilars Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 7.1 Chinese Pharmaceutical Market by Drug Type: Market Size ($bn), Market Share (%), 2014 Table 7.2 Chinese Pharmaceutical Market by Drug Type: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 7.3 Chinese Generic Prescription Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 7.4 Chinese Over-the-Counter Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 7.5 Selected Chinese OTC Drug Manufacturers and Their Activities, 2015 Table 7.6 Chinese Patented Prescription Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 8.1 Hospital Channels Market Size ($bn), Market Share (%), 2014 Table 8.2 Chinese Pharmaceutical Market by Sales Channel: Market Size ($bn), Market Share (%), 2014 Table 8.3 Chinese Pharmaceutical Market by Sales Channel: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 8.4 Chinese Hospital Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 8.5 Number of Healthcare Institutions in China, 2013 Table 8.6 Chinese Retail Pharmacy Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 8.7 Chinese Grassroot Clinics Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 8.8 Chinese Pharmaceutical Sales Through Other Channels: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2015-2025 Table 9.1 Top 50 Domestic Chinese Pharmaceutical Companies: Rank (1-25), Revenue ($bn), Market Share (%), 2014 Table 9.2 Top 50 Domestic Chinese Pharmaceutical Companies: Rank (26-50), Revenue ($bn), Market Share (%), 2014 Table 9.3 Selected Domestic Contract Research Organisations and Their Activities, 2015 Table 9.4 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (A), 2015 Table 9.5 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (B), 2015 Table 9.6 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (D-E), 2015 Table 9.7 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (G-J), 2015 Table 9.8 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (M-N), 2015 Table 9.9 Top 25 Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (O-T), 2015 Table 9.10 Top 10 Multinational Pharmaceutical Companies in the Chinese Pharmaceutical Market: Revenue ($bn), Market Share (%), 2014 Table 12.1 Summary of the Chinese Pharmaceutical Market by Product Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, 2025 Table 12.2 Summary of the Chinese Pharmaceutical Market by Therapy Class: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, 2025 Table 12.3 Summary of Chinese Pharmaceutical Sales Channels: Market Size ($bn), Market Share (%), CAGR (%), 2014, 2019, 2025
List of Figures Figure 1.1 Chinese Pharmaceutical Market Segmentation, 2015 Figure 2.1 China: Annual GDP Growth (%) and Healthcare Expenditure as Total (%) of GDP, 2005-2013 Figure 2.2 Leading Markets and BRIC Countries Healthcare Expenditure: Total (%) of GDP, 2005-2013 Figure 2.3 Out-of-pocket Health Expenditures: (%) of Private Spending on Healthcare, 2005-2013 Figure 3.1 Chinese Pharmaceutical Market: Value Chain, 2015 Figure 3.2 Regional Pharmaceutical Markets of the World: Market Share (%), 2014 Figure 3.3 Chinese Pharmaceutical Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 4.1 Top 5 Broad Causes of Death in China Urban Areas, 2013 Figure 4.2 Top 5 Broad Causes of Death in China Rural Areas, 2013 Figure 4.3 Top 10 Specific Causes of Death in China: Proportion of Overall Deaths (%), 2012 Figure 4.4 Leading Causes of Death in China: Projected Deaths (000s), 2015 and 2025 Figure 5.1 Chinese Pharmaceutical Market by Therapy Area: Market Size ($bn), 2014 Figure 5.2 Chinese Pharmaceutical Market by Therapy Area: Revenue Forecasts ($bn), 2015-2025 Figure 5.3 Chinese Pharmaceutical Market by Therapy Area: Proportional Revenue Increase ($bn), 2015-2025 Figure 5.4 Chinese Pharmaceutical Market by Therapy Area: Market Share (%), 2014 Figure 5.5 Forecast Chinese Pharmaceutical Market by Therapy Area: Market Share (%), 2025 Figure 5.6 Chinese Cardiovascular Disease Market: Segmentation by Drug Class, 2015 Figure 5.7 Chinese Cardiovascular Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.8 Chinese Hypertension Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.9 Chinese Hypertension Market by Drug Class: Market Share (%), 2014 Figure 5.10 Chinese Dyslipidaemia Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.11 Top Companies in the Chinese Hypertension Market: Market Share (%), 2014 Figure 5.12 Chinese Cardiovascular Drugs Market: Drivers and Restraints, 2015-2025 Figure 5.13 Chinese Anticancer Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.14 Incidence of Types of Cancer in China: Incidence (000s), 2015-2025 Figure 5.15 Chinese Anticancer Drugs Market: Drivers and Restraints, 2015-2025 Figure 5.16 Chinese Infectious Disease Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.17 Chinese Antibacterial Drugs Market by Drug Class: Market Share (%), 2014 Figure 5.18 Chinese Infectious Disease Drugs Market: Drivers and Restraints, 2015-2025 Figure 5.19 Chinese Diabetes Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.20 Chinese Diabetes Drugs Market: Drivers and Restraints, 2015-2025 Figure 5.21 Chinese Respiratory Disease Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.22 Chinese COPD Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.23 Chinese Asthma Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.24 Chinese Respiratory Disease Drugs Market: Drivers and Restraints, 2015-2025 Figure 5.25 Chinese CNS Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.26 Chinese Antidepressants Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.27 Chinese CNS Drugs Market: Drivers and Restraints, 2015-2025 Figure 5.28 Chinese Autoimmune Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 5.29 Chinese Autoimmune Drugs Market: Drivers and Restraints, 2015-2025 Figure 6.1 Chinese Pharmaceutical Market by Product Class: Market Size ($bn), 2014 Figure 6.2 Chinese Pharmaceutical Market by Product Class: Revenue Forecasts ($bn), 2015-2025 Figure 6.3 Chinese Pharmaceutical Market by Product Class: Proportional Revenue Increases ($bn), 2015-2025 Figure 6.4 Chinese Small Molecule Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 6.5 Chinese Small Molecule Drugs Market by Product Type: Generic and Branded Drugs Proportional Revenue Increases ($bn), 2015-2025 Figure 6.6 Chinese Small Molecule Drugs Market by Product Type: Generic and Branded Drugs Annual Growth Rate Forecasts (%), 2015-2025 Figure 6.7 Chinese Small Molecule Drugs Market: Drivers and Restraints, 2015-2025 Figure 6.8 Traditional Chinese Medicine Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 6.9 Traditional Chinese Medicine Market: Drivers and Restraints, 2015-2025 Figure 6.10 Chinese Biological Drugs Market by Product Type: Revenue Forecasts ($bn), 2015-2025 Figure 6.11 Chinese Biological Drugs Market by Product Type: Proportional Revenue Increases ($bn), 2015-2025 Figure 6.12 Chinese Branded Biologics Market Forecast: Market Size ($bn), Annual GrowthRate (%), 2015-2025 Figure 6.13 Chinese Vaccines Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 6.14 Chinese Biosimilars Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 6.15 Chinese Biosimilar Manufacturers and Their Product Lines, 2015 Figure 6.16 Chinese Biologics Market: Drivers and Restraints, 2015-2025 Figure 7.1 Chinese Pharmaceutical Market by Drug Type: Market Size ($bn), 2014 Figure 7.2 Chinese Pharmaceutical Market by Drug Type: Market Share (%), 2014 Figure 7.3 Chinese Pharmaceutical Market by Drug Type: Revenue Forecasts ($bn), 2015-2025 Figure 7.4 Chinese Pharmaceutical Market by Drug Type: Proportional Revenue Increase ($bn), 2015-2025 Figure 7.5 Chinese Generic Prescription Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%),2015-2025 Figure 7.6 Chinese Over-the-Counter Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 7.7 Chinese Patented Prescription Drugs Market: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 8.1 Hospital Channels Market Size ($bn), Market Share (%), 2014 Figure 8.2 Chinese Pharmaceutical Market by Sales Channel: Market Size ($bn), 2014 Figure 8.3 Chinese Pharmaceutical Market by Sales Channel: Market Share (%), 2014 Figure 8.4 Chinese Pharmaceutical Market by Sales Channels: Revenue Forecasts ($bn), 2015-2025 Figure 8.5 Chinese Pharmaceutical Market by Sales Channels: Proportional Revenue Increases ($bn), 2015-2025 Figure 8.6 Fragmented Nature of the Chinese Pharmaceutical Distribution Market: Market Share by Revenue for the Leading Five Distributors (%), 2014 Figure 8.7 Chinese Hospital Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 8.8 Chinese Retail Pharmacy Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 8.9 Chinese Grassroot Clinics Sales of Pharmaceuticals: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 8.10 Chinese Pharmaceuticals Sales Through Other Channels: Forecast Market Size ($bn), Annual Growth Rate (%), 2015-2025 Figure 9.1 Top 50 Domestic Chinese Pharmaceutical Companies: Revenue ($bn), 2014 Figure 9.2 Distribution of Pharmaceutical Drugs Revenue by Top 5 and Top 10 Companies in Leading Markets: Market Share (%), 2014 Figure 9.3 Top 10 Multinational Pharmaceutical Companies in the Chinese Pharmaceutical Market: Share (%) of the Total Chinese Pharma Market, 2014 Figure 9.4 Chinese Pharmaceutical Market: Drivers and Restraints for MNCs' Growth, 2015-2025 Figure 11.1 The Rising Middle Class in China: Households With over $7,000 of Disposable Annual Income (millions), Annual Growth Rate, 2014-2030 Figure 11.2 The Ageing Population in China: Number of People Over 65 (millions), Proportion of the Total Population (%), 2014-2030 Figure 12.1 Summary of the Chinese Pharmaceutical Market by Product Class: Market Size ($bn), 2014, 2019, 2025 Figure 12.2 Summary of the Chinese Pharmaceutical Market by Therapy Class: Market Size ($bn), 2014, 2019, 2025 Figure 12.3 Summary of the Chinese Pharmaceutical Sales Channels: Market Size ($bn), 2014, 2019, 2025
3SBio Acambis Agilent Alibaba Group Alliance Boots Amerisource-Bergen Amgen Anhui Anke Biotech AppTech Laboratory Services Asian Cancer Research Group Astellas AstraZeneca Asymchem Laboratories AXM Pharma Baxter Bayer Bayer Healthcare BeiGene Beijing Four Rings Bio-pharmaceutical Beijing Genomics Institute Beijing Kexing Bioproducts Beijing Key Yuan Xinhai Pharmaceutical Beijing SL Pharmaceutical Beijing Taiyang Beijing Tiantan Biological Products Beijing Tong Ren Tang Bio-Bridge Science BiODura Bloomberg Boehringer Ingelheim Bristol-Myers Squibb Buchang Pharma Cardinal Health CASiGEN Pharma Celgene Celsion Corp Changzhou Qianhong Biopharma Chemizon (Beijing) Pharma-Tech Chengdu Di'ao Pharmaceutical Group Chengdu Institutes of Biological Products Chiesi Edding Hong Kong Limited Chi-Med China Chemical & Pharmaceutical Group China Food and Drug Administration (CFDA) China National Accord China National Biotec Group China National Pharmaceutical Group China NT Pharma Group China Pharmaceutical Commerce Association China Pharmaceutical Quality Management Association China Resources Double-Crane Pharmaceuticals China Resources Sanjiu Medical China Shineway Pharmaceutical China Traditional Chinese Medicine Co. ChinaBio Group ChinaGate China Academy of Chinese Medical Sciences Chinese Academy of Sciences (CAS) Chinese Center for Drug Evaluation Chinese Ministry of Commerce Chonqqing Taiji Industry Cipla Consun Pharmaceutical Group Cord Blood America Covance CSPC Pharmaceutical Group Daan Gene Daiichi Sankyo Dalian Hissen Bio-Pharm Dawnrays Pharmaceutical Holdings Diabetes Society Dihon Pharmaceutical Group Dongsheng Pharmaceutical Dr. Reddy’s Laboratories Egret Eisai Eli Lilly Excel PharmaStudies FeRx Incorporated Financial Times Foshan City Furen Pharmaceutical Group Gan & Lee Pharmaceutical Genentech GeneScience Pharmaceuticals Gilead Sciences GlaxoSmithKline Goldman Sachs Guangdong BeiKang Pharmaceutical Guangdong Techpool Guangxi Wuzhou Zhongheng Group Guangzhou Medical University Guangzhou Pharma Guangzhou Pharmaceutical Corporation Guizhou Baiqiang Pharmaceutical Hangzhou East China Pharmaceutical Group Hangzhou Jiuyuan Gene Engineering Hangzhou Tigermed Consulting Hangzhou Zhongmei Huadong Pharmaceutical Harbin Pharmaceutical Group Harbin Tri-Lion Pharmaceutical Harvard University HD Biosciences Henan Lingrui Pharmaceutical Hengrui Henlius Biopharmaceuticals HitGen Hua Medicine Huadong Medicine Hualan Biological Engineering Hualida Biotech Hutchinson Whampoa Hutchison MediPharma i3 Research ICON Inner Mongolia Yili Energy Innovent Biologics JD.com (Jindong Mall) JHL Biotech Jiangsu Chia-tai Tianqing Pharmaceutical Jiangsu Hansen Pharmaceutical Jiangsu Hansoh Pharmaceutical Jiangsu Hengrui Medicine Jiangsu Nhwa Pharmaceutical Jilin Extrawell Changbaishan Jilin Province Huinan Changlong Jinling Pharmaceutical Johnson & Johnson Joincare Pharma JOINN Laboratories Kangmei Pharmaceutical KPC Pharmaceuticals Lepu Medical Livzon Pharmaceutical Group Lundbeck Lundbeck Institute Massachusetts Institute of Technology McKesson Merck & Co. Merck Sharp & Dohme Microport Medical Ministry of Commerce of the People's Republic of China Ministry of Health of the People's Republic of China Ministry of Labor and Social Security of the People's Republic of China Mycenax Mylan Nanjing Kanghai Pharmaceutical Nanjing Pharmaceutical Factory National Development and Reform Commission National Institute for the Control of Pharmaceutical and Biological Products Nestle Health Sciences Nestle SA Newsummit Biopharma North China Pharmaceutical Group Northeast Pharmaceutical Group (NEPG) Northwest University Novartis Novast Laboratories Novo Nordisk Oncobiologics Otsuka Pfizer Pharmaceutical Product Development LLC Pharmaron PKU Healthcare Group Qilu Pharmaceutical Quintiles Roche Sanofi Schering-Plough Servier Shandong Dong-E E-Jiao Shandong Kexing Bioproducts Shandong University Shanghai Celgen Bio-Pharmaceutical Shanghai Charity Foundation Shanghai CP Guojian Pharmaceuticals Shanghai DND Pharm-Technology Shanghai Fosun Pharmaceutical Group Shanghai Furen Industrial Shanghai Institutes of Biological Sciences Shanghai Jinhe Bio-Technology Shanghai Pharmaceuticals Holding ShangPharma Shenzhen Heapalink Shenzhen Kangtai Biological Products Shenzhen Neptunus Bioengineering Shenzhen Salubris Pharmaceuticals Shenzhen Wenle ('Main Luck') Pharmaceutical Shijiazhuang Pharmaceutical Group Shijiazhuang Yiling Shineway Pharmaceutical Group Sichuan Jiufeng Pharmaceutical Sichuan Kelun Pharmaceutical Sichuan Kelun Pharmaceutical Sichuan Yuanda Shuyang Pharmaceutical Sihuan Pharmaceutical Holdings Simcere Pharmaceutical SiniWest Holdings Sino Biological Sino Biopharmaceutical Sinopharm State Key Lab of Respiratory Disease State Traditional Chinese Medicine Administration Sundia MediTech Sundiro Pharma Swiss Re Symbio Pharmaceuticals Takeda Tangshan Yian Bioengineering Tasly Pharmaceuticals Teva The World Bank The Financial Times Thermo Fisher Scientific Tianjin Jin Yao Group Tianjin Kinnovata Pharmaceutical Company Tonghua Dongbao United Pharmatech University of Warwick US Food and Drug Administration Vectura Venturepharm Laboratories Vertex Pharmaceuticals Viva Biotech Wai Yuen Tong Medicine Holdings Walmart Holdings Wanbang Biopharmaceuticals Washington University Weigao Holding Winteam Pharmaceutical Group WHO World Health Organization WTO World Trade Organization WuXi AppTec Xiamen Amoytop Biotech Xian-Janssen Pharmaceuticals Xiuzheng Pharmaceutical Xizang Haisco Yabao Pharmaceutical Group Yangtze River Pharmaceuticals Youcare Pharmaceutical Group Yunnan Baiyao Zai Lab Zendex Bio Strategy Zensun (Shanghai) Sci & Tech Zhejiang Beta Pharma Zhejiang Hisun Pharmaceutical Zhejiang Huahai Pharmaceutical Zhejiang Medicine Zhejiang Tianyuan Zhenjian Hisun Pharmaceuticals Zhuhai United States Labs Zuellig Pharma China
Download sample pages
Complete the form below to download your free sample pages for Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Chinese Pharmaceuticals Market: Trends, Reforms, Opportunities and Revenue Prospects 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Cancer Diagnostics Market Report 2021-2031
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.
Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030
The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.
Visiongain Publishes Cell-Based Assays Market Report to 2030
Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.
Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
